In some cancer models, this was potentiated by ICB therapies, including anti-PD-1 therapy with or without radiation, anti-CTLA4 therapy, or a 4-1BB agonist (Dodagatta-Marri et al. 2021). Here, PDCD1 is linked to cancer.